Press Releases Beam Therapeutics Inc.

Stocks

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
32.68 ^USD	-8.77%		-6.06%	+17.89%

07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise	MT
07-08	Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration	MT

Press Releases

06-18	Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration	GL
05-18	Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference	GL
05-13	Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference	GL
05-12	Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026	GL
05-07	Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates	GL
04-01	Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine	GL
03-25	Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development	GL
02-24	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street	GL
02-24	Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street	AQ
02-24	Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)	GL
02-23	Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program	GL
01-11	Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition	GL
12-18	Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
12-06	Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting	GL
11-12	Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference	GL
11-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	GL
11-04	Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates	AQ
11-03	Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting	GL
25/08/25	Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences	GL
14/08/25	Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	GL
05/08/25	Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)	GL
13/06/25	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress	GL
03/06/25	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease	GL
29/05/25	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	GL
29/05/25	Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)	AQ